Evidence map›Paper›PMID 33099659›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2021

A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy.

A Paschali, E Panagiotidis, T Triantafyllou, V Palaska, K Tsirou, E Verrou, E Υiannaki, D Markala, A Papanikolaou, A Pouli and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. The [European journal of nuclear medicine and molecular imaging · 2026
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Clinical value ofCellular oncology (Dordrecht, Netherlands) · 2024
    Article
  6. Article
  7. Article
  8. Hybrid simultaneous whole-body 2-[European radiology · 2023
    Article
  9. International journal of molecular sciences · 2022
    Article
  10. Progress of modern imaging modalities in multiple myeloma.International journal of hematology · 2022
    Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

A PaschaliDepartment of Nuclear Medicine, Theagenion Cancer Hospital, Thessaloniki, Greece. anna.pashali@gmail.com.ORCID http://orcid.org/0000-0002-7157-8569
E PanagiotidisDepartment of Nuclear Medicine, Theagenion Cancer Hospital, Thessaloniki, Greece.
T TriantafyllouDepartment of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece.
V PalaskaDepartment of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece.
K TsirouDepartment of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece.
E VerrouDepartment of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece.
E ΥiannakiHematology/Flow cytometry Lab, Theagenion Cancer Hospital, Thessaloniki, Greece.
D MarkalaHematology/Flow cytometry Lab, Theagenion Cancer Hospital, Thessaloniki, Greece.
A PapanikolaouHematopathology Department, Evangelismos General Hospital, Athens, Greece.
A PouliHematology Department, "St Savvas" Oncology Hospital, Athens, Greece.
P KonstantinidouDepartment of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece.
V ChatzipavlidouDepartment of Nuclear Medicine, Theagenion Cancer Hospital, Thessaloniki, Greece.
E TerposDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
E KatodritouDepartment of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece.
Theageneio General Hospital · GREvangelismos Hospital · GRNational and Kapodistrian University of Athens · GRSt Savas Hospital · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe investigation of a semi-quantitative index in the pelvis to assess for diffuse bone marrow (BM) [18F]-FDG uptake and the investigation of PET skeletal patterns in multiple myeloma (MM) patients, in accordance with prognostic markers, clonal plasma cell (cPC) morphology, and response to therapy.

methodsWe prospectively analyzed [18F]-FDG PET/CT in 90 MM patients (newly diagnosed, 60; relapsed/refractory, 30). Among other PET/CT parameters, we calculated the ratio SUVmax pelvis/liver and examined for correlations with known MM prognostic parameters, cPC morphology (good vs. low/intermediate differentiation), and response to therapy.

resultsSUVmax pelvis/liver ratio was significantly lower for the group of good differentiation vs. intermediate/low differentiation cPCs (p < 0.001) and showed a positive correlation with BM infiltration rate, β2 microglobulin, serum ferritin, international staging system (ISS), and revised ISS; no significant correlation was found with hemoglobin. A cutoff value of 1.1 showed an excellent specificity (99%) and high sensitivity (76%) for diffuse BM involvement (AUC 0.94; p < 0.001). Mixed pattern and appendicular involvement correlated with poor prognostic features while normal pattern, found in 30% of patients, correlated with good prognostic features. Presence of ≥ 10 focal lesions negatively predicted for overall response (p < 0.05; OR 4.8). The CT component improved the diagnostic performance of PET.

conclusionThis study showed, for the first time, that cPC morphology and markers related with MM biology, correlate with SUVmax pelvis/liver index, which could be used as a surrogate marker for BM assessment and disease prognosis; PET patterns correlate with MM prognostic features and response rates.

Indexed as

Fluorodeoxyglucose F18Multiple MyelomaBone MarrowHumansPlasma CellsPositron Emission Tomography Computed TomographyPrognosisRadiopharmaceuticalsRetrospective StudiesFluorodeoxyglucose F18Radiopharmaceuticals[18F]-FDGMultiple myelomaPET/CTPlasma cell morphologyPrognostic markers

Identifiers

PMID33099659
OpenAlexW3093784492

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.